Skip to main content
Two people smiling and pointing at camera

A new way forward

PEGASUS (NCT03533257) was a Phase 2a, randomized, placebo-controlled trial in 95 participants in the U.S. evaluating safety, tolerability, neurobiological activity, and preliminary clinical efficacy of AMX0035 in a broad range of participants with early dementia or late mild cognitive impairment due to Alzheimer’s disease.

Trial update

The PEGASUS trial has completed and top line results were presented in November 2021. Read more details in this press release (opens new window).

Our commitment

At Amylyx, we are relentlessly driven by a commitment to those living with neurodegenerative diseases. We work collaboratively across everything we do, aspiring to help support and create more moments for the neurodegenerative community.

Clinical trials

Our innovative approach to developing  transformative therapeutics has far-reaching potential to  improve the management of multiple neurodegenerative  diseases. Learn more about our clinical trials. 

Latest News